$CAPR (Capricor Therapeutics, Inc.)

$CAPR {{ '2016-09-16T11:50:41+0000' | timeago}} • Announcement

$CAPR announced it intends to offer shares of its common stock in an underwritten public offering. The public offering will be made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) on Sept. 28, 2015 and declared effective by the SEC on Oct. 26, 2015.

$BAX {{ '2018-01-22T21:30:01+0000' | timeago}} • Announcement

$BAX announced the FDA approval of Bivalirudin in 0.9% Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), a common non-surgical procedure to treat blocked or narrowed blood vessels in the heart.

$LIVN {{ '2018-01-11T17:37:05+0000' | timeago}} • Announcement

$LIVN said the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant Study. The study is expected to enroll about 230 patients at 15 sites from the U.S. and Canada to ascertain whether valve leaflets are fully operational following surgery.

$LIVN {{ '2018-01-08T14:58:25+0000' | timeago}} • Announcement

$LIVN announced Matthew J. Dodds has joined the company as SVP, Corporate Development. In this role, Dodds is responsible for Business Development, Investor Relations and Corporate Communications.

$BAX {{ '2018-01-08T14:03:11+0000' | timeago}} • Announcement

$BAX will acquire two products from Mallinckrodt plc, RECOTHROM Thrombin topical and PREVELEAK Surgical Sealant, for an upfront payment of approx. $153MM and potential contingent payments in future. The deal is expected to be modestly accretive to 2018 adjusted earnings and increasingly accretive thereafter and is expected to close in 1H18.

$ZBH {{ '2018-01-04T11:55:45+0000' | timeago}} • Announcement

$ZBH received FDA clearance for the Sidus Stem-Free Shoulder system. This is a total shoulder arthroplasty solution for patients with good bone stock that have either osteoarthritis, post-traumatic arthrosis, focal avascular necrosis of the humeral head or who had previous surgeries of the shoulder that do not compromise the fixation.

$ZBH {{ '2017-12-26T12:15:53+0000' | timeago}} • Announcement

$ZBH announced positive results from a pilot study demonstrating the safety and efficacy of the nSTRIDE Autologous Protein Solution  Kit for the treatment of knee osteoarthritis, the most common type of arthritis.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$ZBH {{ '2017-12-19T13:16:30+0000' | timeago}} • Announcement

Healthcare company $ZBH has approved a cash dividend of $0.24 per share on its common stock, for the fourth quarter. The dividend is payable on or about January 29, 2018, to stockholders of record on December 29, 2017.

$LIVN {{ '2017-12-05T14:44:32+0000' | timeago}} • Announcement

$LIVN has agreed to acquire the remaining outstanding interests in ImThera Medical, Inc. for approx. $225MM. Up-front costs are approx. $78MM with the balance paid on a schedule driven by regulatory and sales milestones. The deal is projected to be near-term accretive and is expected to close in early 2018.

$LIVN {{ '2017-11-20T12:54:20+0000' | timeago}} • Announcement

$LIVN and MicroPort Scientific Corporation have entered into a binding Letter of Intent for the sale of LivaNova’s Cardiac Rhythm Management Business Franchise to MicroPort for $190MM in cash. The companies expect the transaction to close in the second quarter of 2018.

$BAX {{ '2017-11-14T15:45:06+0000' | timeago}} • Announcement

$BAX's BoD declared a quarterly dividend of $0.16 per share of common stock. The dividend is payable on Jan. 2, 2018, to stockholders of record as of Dec. 1, 2017. The indicated annual dividend rate is $0.64 per share.

$BAX {{ '2017-11-07T15:21:25+0000' | timeago}} • Announcement

$BAX presented new data on Sharesource telehealth platform in helping the clinical management of peritoneal dialysis (PD) patients. The exploratory studies show how Sharesource data may provide an early indicator of impending peritonitis, or evidence of PD catheter dysfunction.

$ZBH {{ '2017-11-01T13:59:52+0000' | timeago}} • Infographic

$ZBH Zimmer Biomet Holdings, Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$BAX {{ '2017-10-25T15:34:40+0000' | timeago}} • Infographic

$BAX Baxter International Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$BAX {{ '2017-10-25T14:30:11+0000' | timeago}} • Announcement

$BAX now projects full-year 2017 sales growth of about 4% on a reported basis, about 4% on a constant currency basis, and about 4-5% operationally. EPS from continuing operations, before special items, are now expected to be $2.40-2.43.

$BAX {{ '2017-10-25T14:29:01+0000' | timeago}} • Announcement

$BAX now projects 4Q17 revenues to be negatively impacted by about $70MM due to the temporary manufacturing disruptions resulting from Hurricane Maria. For 4Q17, $BAX sees sales growth of 4-5% on a reported basis, about 2% on a constant currency basis and 1-2% operationally. $BAX sees EPS, before special items, of $0.56-0.59.

$BAX {{ '2017-10-25T14:24:47+0000' | timeago}} • Announcement

$BAX's Renal sales for 3Q17 were about $1Bil, representing an increase of 3% on both a reported basis and constant currency basis. Operationally, Renal sales advanced 6% in the quarter driven by improved performance across all major product lines and therapies globally.

$BAX {{ '2017-10-25T14:23:44+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products for 3Q17 advanced 7% from last year. Performance benefited from continued strength in U.S. fluid systems business as well as favorable demand for injectable pharmaceuticals. Sales also benefited from increased sales of anesthesia and critical care products as well as hospital pharmacy compounding services.

$BAX {{ '2017-10-25T14:20:40+0000' | timeago}} • Announcement

$BAX's sales within the U.S. for 3Q17 were about $1.1Bil, advancing 8%. International sales totaled about $1.6Bil, representing a 5% increase on a reported basis and a 4% rise on a constant currency basis. Baxter's operational sales rose 7% in the U.S. and 6% internationally.

$BAX {{ '2017-10-25T14:18:41+0000' | timeago}} • Announcement

$BAX reported a jump in 3Q17 earnings driven by lower costs and expenses as well as its continued focus on disciplined execution. Net income rose to $251MM or $0.45 per share from $130MM or $0.24 per share last year. Net sales grew 6% to $2.71Bil. Adjusted EPS increased 14% to $0.64.

Recent Transcripts

DLTH (Duluth Holdings Inc.)
Thursday, December 7 2017 - 2:30pm
CYTX (Cytori Therapeutics, Inc.)
Thursday, November 9 2017 - 10:30pm
SGRY (Surgery Partners, Inc.)
Thursday, November 9 2017 - 1:30pm
ATHX (Athersys, Inc.)
Wednesday, November 8 2017 - 9:30pm
CSWI (CSW Industrials, Inc.)
Wednesday, November 8 2017 - 3:00pm
VCEL (Vericel Corporation)
Tuesday, November 7 2017 - 1:00pm
VYGR (Voyager Therapeutics, Inc.)
Thursday, November 2 2017 - 8:30pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
EDGE (Edge Therapeutics, Inc.)
Wednesday, November 1 2017 - 12:30pm
ZBH (Zimmer Biomet Holdings, Inc.)
Wednesday, November 1 2017 - 12:00pm
NVCR (NovoCure Limited)
Thursday, October 26 2017 - 12:00pm
BAX (Baxter International Inc.)
Wednesday, October 25 2017 - 12:30pm
EQBK (Equity Bancshares, Inc.)
Friday, October 20 2017 - 2:00pm
DLTH (Duluth Holdings Inc.)
Tuesday, September 5 2017 - 8:30pm
CYTX (Cytori Therapeutics, Inc.)
Thursday, August 10 2017 - 9:30pm
ATHX (Athersys, Inc.)
Wednesday, August 9 2017 - 8:30pm
CSWI (CSW Industrials, Inc.)
Wednesday, August 9 2017 - 2:00pm
LIVN (LivaNova PLC)
Wednesday, August 9 2017 - 1:00pm
SGRY (Surgery Partners, Inc.)
Wednesday, August 9 2017 - 12:30pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm

AlphaGraphics you may like